Maze Therapeutics (MAZE) Other Accumulated Expenses (2024 - 2026)

Maze Therapeutics has reported Other Accumulated Expenses for 3 years, with the latest figure at $438000.0 in Q1 2026.

• Quarterly Other Accumulated Expenses changed N/A year-over-year to $438000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $438000.0 (changed N/A YoY) and the FY2025 annual result came in at $149000.0, down 75.89% from the prior year.
• Other Accumulated Expenses grew to $438000.0 in Q1 2026 per MAZE's latest filing, from $149000.0 in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $5.1 million in Q3 2025 and troughed at $53000.0 in Q2 2025.
• A 3-year average of $1.3 million and a median of $438000.0 in 2026 frame the typical range for Other Accumulated Expenses.
• The widest YoY moves for Other Accumulated Expenses: up 75.89% in 2025, down 75.89% in 2025.
• Over 3 years, Other Accumulated Expenses stood at $618000.0 in 2024, then tumbled by 75.89% to $149000.0 in 2025, then soared by 193.96% to $438000.0 in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $438000.0, $149000.0, and $5.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.